Skip to main content

Olon presents biotech plan

Italian CDMO and API supplier Olon has presented a two-year, €30 million plan to expand its Settimo Torinese Biotech Hub near Turin. This focuses on microbial fermentation and is claimed to have “some of the most extensive know-how” on the subject in Europe”. The plan focuses on therapeutic peptides based on Olon’s expertise in the development of rDNA peptides and proteins.

Olon Biotech division launched

Italian firm Olon has presented its new division, Olon Biotech, which will offer CDMO services at industrial scale. These based on microbial fermentation processes using bacteria, yeast and fungi and will include high potency. It will also have proprietary products for industries including health and pharma, food, cosmetics, flavours and fragrances.

Olon begins R&D centre

Italian CDMO Olon is to invest €10 million to create an R&D hub at its headquarters site at Rodano near Milan. This will integrate seven existing R&D centres and will be dedicated entirely to research laboratories to be used to develop APIs and manufacturing processes. 

Construction has started and is due to be completed in Q2 2023. This will also lead to about 50 new researchers being hired, bringing the corporate total to around 350.

Olon announces HPAPI milestone

Italian CDMO Olon has completed a large-scale high containment production line (OEL < 1 mg/m3) at its Rodano site at a cost of about €10 million. This is part of a planned €27 million it will roll out over 2022-3 that is fully allocated to the expansion of further internal expertise and capacity of high containment production. The new line, which is already operative, enables Olon to produce HPAPIs in batches of 30-250 kg.

Olon in biocontrols agreement

Italian CDMO Olon has reached a long-term strategic partnership for the manufacturing of the protein-based biocontrol products of Belgium’s Biotalys. This, the companies said, will secure the global supply of Biotalys’ first product, Evoca, a biofungicide that is planned for market introduction in the US in 2H 2022, subject to regulatory approval. 

Major pipeline growth for Olon

At CPhI Worldwide 2021 in Milan on 9-11 November, Italian CDMO Olon announced “a significant expansion of its pipeline of APIs, a result of its R&D investment strategy”. In all, it has added nine new active substances for the generics market by investing across several lines and at multiple facilities in its network.

Olon in enzymatic expansion

In partnership with Aguettant Pharmarmaceutical, Italy’s Olon Group is to expand and renovate its plant in Mulazzano, which is dedicated to the production by enzymatic transformation. It will install reactors, filters and ancillary equipment, as well as automating and digitalising some steps performed there.

Subscribe to Olon